$ CUR - Neuralstem ALS Stem Cell Trial Results Reported in, STEM CELLS

Neuralstem (AMEX: CUR) is working on Fetal Derived cells for Lou Gehrig’s disease. The company received a lot of press a few years ago when CNN (Sanjay Gupta) featured the treatment.

• The company announced that safety results from the first 12 patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) to receive its stem cells were reported online in the peer-reviewed publication, STEM CELLS, on 13-Mar.
• The report was titled "Lumbar Intraspinal Injection of Neural Stem Cells in Patients with ALS: Results of a Phase I Trial in 12 Patients".
• One patient has shown improvement in his clinical status, even though researchers caution that the study was not designed to show efficacy.
• There was no evidence of accelerated disease progression due to the intervention in any of the 12 patients, who were followed from 6-18 months after they were transplanted with the cells.
• All of the patients, who received transplants in the lumbar (lower back) region, tolerated the treatment without any long-term complications related to either the surgery or the cells.

See the full press release.

Flash Player 9 or higher is required to view the chart
Click here to download Flash Player noThe company announced that safety results from the first 12 patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) to receive its stem cells were reported online in the peer-reviewed publication, STEM CELLS, on 13-Mar.he company announced that safety results from the first 12 patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) to receive its stem cells were reported online in the peer-reviewed publication, STEM CELLS, on 13-Mar.

Flash Player 9 or higher is required to view the chart
Click here to download Flash Player now

View the full CUR chart at Wikinvest